(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.35%.
60 Degrees Pharmaceuticals's earnings in 2025 is -$8,299,494.On average, 1 Wall Street analyst forecast SXTP's earnings for 2025 to be -$20,193,987, with the lowest SXTP earnings forecast at -$20,193,987, and the highest SXTP earnings forecast at -$20,193,987. On average, 1 Wall Street analyst forecast SXTP's earnings for 2026 to be -$21,999,954, with the lowest SXTP earnings forecast at -$21,999,954, and the highest SXTP earnings forecast at -$21,999,954.
In 2027, SXTP is forecast to generate -$1,929,100 in earnings, with the lowest earnings forecast at -$1,929,100 and the highest earnings forecast at -$1,929,100.